These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38452922)

  • 1. Small molecule drug metabolite synthesis and identification: why, when and how?
    Shanu-Wilson J; Coe S; Evans L; Steele J; Wrigley S
    Drug Discov Today; 2024 May; 29(5):103943. PubMed ID: 38452922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologically active drug metabolites: impact on drug discovery and pharmacotherapy.
    Obach RS
    Pharmacol Rev; 2013 Apr; 65(2):578-640. PubMed ID: 23406671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemical metabolite synthesis and profiling: Mimicking in vivo biotransformation reactions.
    Chhatrapati Bisen A; Nashik Sanap S; Agrawal S; Biswas A; Sankar Bhatta R
    Bioorg Chem; 2023 Oct; 139():106722. PubMed ID: 37453238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conventional and novel approaches in generating and characterization of reactive intermediates from drugs/drug candidates.
    Orhan H; Vermeulen NP
    Curr Drug Metab; 2011 May; 12(4):383-94. PubMed ID: 21395525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug metabolites as cytochrome p450 inhibitors: a retrospective analysis and proposed algorithm for evaluation of the pharmacokinetic interaction potential of metabolites in drug discovery and development.
    Callegari E; Kalgutkar AS; Leung L; Obach RS; Plowchalk DR; Tse S
    Drug Metab Dispos; 2013 Dec; 41(12):2047-55. PubMed ID: 23792812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of relative MS response factors of drug metabolites for semi-quantitative assessment of chemical liabilities in drug discovery.
    Blanz J; Williams G; Dayer J; Délémonté T; Gertsch W; Ramstein P; Aichholz R; Trunzer M; Pearson D
    J Mass Spectrom; 2017 Apr; 52(4):210-217. PubMed ID: 28152561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microbial biotransformation - an important tool for the study of drug metabolism.
    Salter R; Beshore DC; Colletti SL; Evans L; Gong Y; Helmy R; Liu Y; Maciolek CM; Martin G; Pajkovic N; Phipps R; Small J; Steele J; de Vries R; Williams H; Martin IJ
    Xenobiotica; 2019 Aug; 49(8):877-886. PubMed ID: 30118378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cunninghamella Biotransformation--Similarities to Human Drug Metabolism and Its Relevance for the Drug Discovery Process.
    Piska K; Żelaszczyk D; Jamrozik M; Kubowicz-Kwaśny P; Pękala E
    Curr Drug Metab; 2016; 17(2):107-17. PubMed ID: 26526834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liquid chromatography-mass spectrometry in in vitro drug metabolite screening.
    Tolonen A; Turpeinen M; Pelkonen O
    Drug Discov Today; 2009 Feb; 14(3-4):120-33. PubMed ID: 19059358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of pharmacologically active metabolites in drug discovery and development.
    Fura A
    Drug Discov Today; 2006 Feb; 11(3-4):133-42. PubMed ID: 16533711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolite interference in pharmacokinetic studies.
    Moghaddam MF; Fan JH; Tang Y; Khatsenko O; Katz JC; Shirley MA
    Drug Metab Lett; 2007 Dec; 1(4):272-5. PubMed ID: 19356054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An industry perspective on tiered approach to the investigation of metabolites in drug development.
    Huskey SE; Li W; Mangold JB; Flarakos J
    Bioanalysis; 2014 Mar; 6(5):617-28. PubMed ID: 24620804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analytical tools and approaches for metabolite identification in early drug discovery.
    Chen Y; Monshouwer M; Fitch WL
    Pharm Res; 2007 Feb; 24(2):248-57. PubMed ID: 17048114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic stability and its role in the discovery of new chemical entities.
    Słoczyńska K; Gunia-Krzyżak A; Koczurkiewicz P; Wójcik-Pszczoła K; Żelaszczyk D; Popiół J; Pękala E
    Acta Pharm; 2019 Sep; 69(3):345-361. PubMed ID: 31259741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Database Extraction of Metabolite Information of Drug Candidates: Analysis of 27 AstraZeneca Compounds with Human Absorption, Distribution, Metabolism, and Excretion Data.
    Iegre J; Hayes MA; Thompson RA; Weidolf L; Isin EM
    Drug Metab Dispos; 2016 May; 44(5):732-40. PubMed ID: 26868617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applicability of bioanalysis of multiple analytes in drug discovery and development: review of select case studies including assay development considerations.
    Srinivas NR
    Biomed Chromatogr; 2006 May; 20(5):383-414. PubMed ID: 16307470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug metabolism and metabolite safety assessment in drug discovery and development.
    He C; Wan H
    Expert Opin Drug Metab Toxicol; 2018 Oct; 14(10):1071-1085. PubMed ID: 30215280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active drug metabolites and renal failure.
    Drayer DE
    Am J Med; 1977 Apr; 62(4):486-9. PubMed ID: 851118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
    Stepan AF; Walker DP; Bauman J; Price DA; Baillie TA; Kalgutkar AS; Aleo MD
    Chem Res Toxicol; 2011 Sep; 24(9):1345-410. PubMed ID: 21702456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and characterization of reactive metabolites in natural products-driven drug discovery.
    Njuguna NM; Masimirembwa C; Chibale K
    J Nat Prod; 2012 Mar; 75(3):507-13. PubMed ID: 22296642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.